EU: Stakes High For Novartis At Latest CHMP Meeting
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.
You may also be interested in...
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.